kapeaUVB

KapeaUVB is a term used to describe narrow-band ultraviolet B phototherapy, a medical treatment that uses a narrow range of UVB wavelengths, typically around 311 to 313 nanometers. The goal of the narrow spectrum is to achieve therapeutic effects at lower doses with fewer side effects compared to broader UVB light.

Mechanism and practice. Narrow-band UVB acts by inhibiting abnormal keratinocyte proliferation and modulating local immune responses in the skin. The treatment is delivered in specialized phototherapy units, often using TL-01 fluorescent lamps or newer LED-based devices; some settings also use targeted excimer lasers for specific lesions. Dose is individualized through concepts such as the minimal erythema dose (MED) to balance efficacy and safety.

Clinical indications. KapeaUVB is routinely used in dermatology for conditions including plaque psoriasis, atopic dermatitis (eczema), vitiligo, and certain forms of cutaneous T-cell lymphoma. It is commonly employed as first-line phototherapy for psoriasis and as part of regimens aiming to induce repigmentation in vitiligo. Treatment response varies with disease severity, skin type, and treatment duration.

Protocol and safety. Treatments are typically administered two to three times weekly over several weeks to months, with dose adjustments based on skin response. Common short-term adverse effects include erythema (redness), dryness, and itch. Long-term risks are primarily tied to cumulative UV exposure; compared with broadband UVB, narrow-band UVB is generally considered to have a favorable safety profile, though ongoing monitoring by clinicians is advised. Eye protection is recommended during sessions to prevent ocular exposure.